Literature DB >> 24337483

Quality of life among long-term survivors of head and neck cancer treated by intensity-modulated radiotherapy.

Allen M Chen1, Megan E Daly1, D Gregory Farwell2, Esther Vazquez1, Jean Courquin1, Derick H Lau3, James A Purdy1.   

Abstract

IMPORTANCE: Radiation therapy to the head and neck has traditionally been associated with adverse effects that can affect oral health and physical functioning. Although intensity-modulated radiotherapy (IMRT) has been widely adopted as a means of decreasing toxic effects, limited clinical data exist on its potential effect on long-term quality of life.
OBJECTIVE: To analyze quality of life among long-term survivors of head and neck cancer treated with IMRT. DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional analysis studied 50 consecutive long-term survivors of head and neck cancer from a comprehensive cancer center who had previously undergone IMRT that required bilateral neck irradiation for locally advanced disease. All patients were clinically without evidence of recurrent disease and had at least 5 years of follow-up. MAIN OUTCOMES AND MEASURES: The University of Washington Quality of Life (UW-QOL) scores were reviewed for all study participants. The UW-QOL questionnaire consists of 12 domains that pertain to the degree of quality of life in the categories of pain, appearance, activity, recreation, swallowing, chewing, speech, shoulder function, taste, saliva, mood, and anxiety.
RESULTS: Five years after completion of IMRT, 42 patients (84%) reported that their health-related quality of life was "much better" or "somewhat better" than at the time of cancer diagnosis. With respect to recent health-related quality of life during the preceding 7 days at the time of completing the UW-QOL questionnaire, 40 patients (80%) treated with IMRT reported "outstanding" or "very good" levels of functioning. Five years after completion of treatment, 41 (82%) rated their overall quality of life as "outstanding" or "very good." The lowest domain score on the UW-QOL questionnaire at 5 years pertained to salivary dysfunction. However, 42 patients (84%) reported saliva "of normal consistency" or "less saliva than normal but enough" compared with 8 (16%) reporting "too little saliva." No patient reported having "no saliva." CONCLUSIONS AND RELEVANCE: Our findings add to the body of literature that supports the acceptance of IMRT as standard treatment for head and neck cancer. The fact that most 5-year survivors were satisfied with their quality of lives points to the ability of IMRT to preserve long-term functioning.

Entities:  

Mesh:

Year:  2014        PMID: 24337483     DOI: 10.1001/jamaoto.2013.5988

Source DB:  PubMed          Journal:  JAMA Otolaryngol Head Neck Surg        ISSN: 2168-6181            Impact factor:   6.223


  23 in total

1.  Trends in the 15D health-related quality of life over the first year following diagnosis of head and neck cancer.

Authors:  K Aro; L Bäck; V Loimu; K Saarilahti; S Rogers; H Sintonen; R Roine; Antti Mäkitie
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-07-28       Impact factor: 2.503

Review 2.  Body image: a critical psychosocial issue for patients with head and neck cancer.

Authors:  Michelle Cororve Fingeret; Irene Teo; Keelan Goettsch
Journal:  Curr Oncol Rep       Date:  2015-01       Impact factor: 5.075

3.  Sino-nasal mucosal malignant melanoma.

Authors:  Muneeb Uddin Karim; Khursheed Khan; Nasir Ali; Mubasher Ikram
Journal:  BMJ Case Rep       Date:  2015-04-29

4.  'What will I be like' after my diagnosis of head and neck cancer?

Authors:  S N Rogers; E S Hogg; W K A Cheung; L K L Lai; P Jassal; D Lowe; A Kanatas
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-07-22       Impact factor: 2.503

5.  Health-related quality of life of head and neck cancer patients with successful oncological treatment.

Authors:  V Loimu; A A Mäkitie; L J Bäck; H Sintonen; P Räsänen; R Roine; K Saarilahti
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-07-02       Impact factor: 2.503

6.  Patient-reported quality-of-life outcomes after de-escalated chemoradiation for human papillomavirus-positive oropharyngeal carcinoma: Findings from a phase 2 trial.

Authors:  John V Hegde; Narek Shaverdian; Megan E Daly; Carol Felix; Deborah L Wong; Michael H Rosove; Jordan H Garst; Pin-Chieh Wang; Darlene Veruttipong; Shyam Rao; Ruben C Fragoso; Jonathan W Riess; Michael L Steinberg; Allen M Chen
Journal:  Cancer       Date:  2017-10-17       Impact factor: 6.860

7.  Clinical and sociodemographic factors that affect the quality of life of survivors of head and neck cancer.

Authors:  Laura Izabel Lampert Bonzanini; Eloisa Barbieri Soldera; Gabriela Barbieri Ortigara; Riéli Elis Schulz; Raquel Pippi Antoniazzi; Thiago Machado Ardenghi; Kívia Linhares Ferrazzo
Journal:  Support Care Cancer       Date:  2019-08-02       Impact factor: 3.603

Review 8.  Optimizing Treatment De-Escalation in Head and Neck Cancer: Current and Future Perspectives.

Authors:  Ari J Rosenberg; Everett E Vokes
Journal:  Oncologist       Date:  2020-09-21

9.  CTV Guidance for Head and Neck Cancers.

Authors:  Beth M Beadle; Carryn M Anderson
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-03-15       Impact factor: 7.038

10.  Cervical nodal level V can safely be omitted in the treatment of locally advanced oropharyngeal squamous cell carcinoma with definitive IMRT.

Authors:  Stanley Gutiontov; Jonathan Leeman; Benjamin Lok; Paul Romesser; Nadeem Riaz; C Jillian Tsai; Nancy Lee; Sean McBride
Journal:  Oral Oncol       Date:  2016-05-27       Impact factor: 5.337

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.